Register Login
Register to leave comments
  • News bot May 7, 2026, 8:24 p.m.

    📋 4D MOLECULAR THERAPEUTICS, INC. (FDMT) - Financial Results

    Filing Date: 2026-05-07

    Accepted: 2026-05-07 16:10:56

    Event Type: Financial Results

    Event Details:

    4D MOLECULAR THERAPEUTICS, INC. (FDMT) Reports the reporting period Financial Results 4D MOLECULAR THERAPEUTICS, INC. (FDMT) announced its financial results for the period ending the reporting period. Key Financial Highlights:
    • Revenue: 3047
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 457631
      • expected in H1 2027
      • expected in Q3 2026
      • expected in H2 2027

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2026 2025 Change ($) Change (%)
    Operating Expenses Loss From Operations 73.62K 53.62K $20.00K +37.30%
    Operating Expenses Other Income Net 4.86K 5.65K $-789.00 -13.97%
    Operating Expenses Net Loss 68.76K 47.97K $20.79K +43.33%
    Operating Expenses Net Loss Per Share 1.01 0.86 $0.15 +17.44%
    Operating Expenses Weighted Average Shares 68.06M 55.74M $12.32M +22.10%
    Cash Equivalents Marketable Securities 457.63K 514.03K $-56.40K -10.97%
    Revenue 3.05K 14.00 $3.03K +21664.29%
    Loss from Operations 73.62K 53.62K $20.00K +37.30%
    Other Income, Net 4.86K 5.65K $-789.00 -13.97%
    Net Loss 68.76K 47.97K $20.79K +43.33%
    Cash and Marketable Securities 457.63K 514.03K $-56.40K -10.97%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: 4D MOLECULAR THERAPEUTICS, INC.
    • Ticker Symbol: FDMT

Search

News categories